# CVL237 Tablets for APDS/PASLI

> **NCT06293716** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Convalife (Shanghai) Co., Ltd.** · enrollment: 35 (estimated)

## Conditions studied

- PI3K and P110delta Hyperactivation Syndrome

## Interventions

- **DRUG:** CVL237 tablets
- **DRUG:** CVL237 placebo tablets

## Key facts

- **NCT ID:** NCT06293716
- **Lead sponsor:** Convalife (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-30
- **Primary completion:** 2025-12-29
- **Final completion:** 2026-03-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06293716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06293716, "CVL237 Tablets for APDS/PASLI". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06293716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*